Probabilities |
Probabilities |
Probabilities |
Probabilities |
HR for tumor growth of BRAFV600E positive vs.
BRAFV600E negative |
3.55 |
3 |
4 |
HR for tumor recurrence of BRAFV600E positive
vs. BRAFV600E negative |
3.55 |
3 |
4 |
Probability of a long-term complication from HT |
0.0154 |
0.013 |
0.017 |
Probability of growth of the primary tumor during AS for patients aged
40–59 years old |
0.0091 |
0.0082 |
0.01 |
Probability of growth of the primary tumor during AS for patients more
than 60 years old |
0.004 |
0.0036 |
0.0044 |
Probability of loco-regional disease during AS for patients aged 40–59
years old |
0.0023 |
0.0021 |
0.0025 |
Probability of loco-regional disease during AS for patients more than 60
years old |
0.00050 |
0.00045 |
0.00055 |
Probability of recurrence after HT |
0.00400 |
0.003 |
0.005 |
Model structure variables |
Model
structure variables |
Model structure variables |
Model structure variables |
Age |
40 |
35 |
45 |
Discount rate |
0 |
0 |
0.05 |
Time horizon |
100 |
90 |
110 |
Utilities values |
Utilities values |
Utilities values |
Utilities values |
Utility during AS health state |
0.88 |
0.8 |
1 |
Utility of disease recurrence |
0.54 |
0.5 |
0.7 |
Utility of disease-free state after HT with complication |
0.63 |
0.5 |
0.7 |
Utility of disease-free state after HT without complication |
0.99 |
0.8 |
1 |